TICKERNERD
Menu
PTNPTNHealthcare · Biotechnology

PTN Stock Forecast: Palatin Technologies, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$9.69
−5.00% on the day

The 3 Wall Street analysts covering Palatin Technologies, Inc. hold a median 12-month price target of $53 — +447.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$17.2M
Ticker Nerd rank
43 / 100
Median analyst target
$53
Analysts covering
3
Total return, dividends reinvested
1W
+3.5%
1M
+12.4%
YTD
−37.0%
1Y
−3.2%
From 52W high
−65.4%
From 52W low
+68.5%
$6
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PTN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Palatin Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
43 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
97
Size
90
Volatility
67
Revisions
60
Value
57
Momentum
24
Quality
18
Issuance
18
Accruals
17

Growth (97): Sales and profits are climbing, and climbing faster than before.

Accruals (17): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PTN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PTN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26PTNHigh $60Median $53Low $48

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $48Median $53High $60

The green dot is the last close — the median target sits +447.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Dec 2025Laidlaw & Co.InitiatesBuy—
13 Feb 2025HC Wainwright & Co.MaintainsBuy—
7 Feb 2025HC Wainwright & Co.ReiteratesBuy—
19 Dec 2024HC Wainwright & Co.ReiteratesBuy—
25 Nov 2024HC Wainwright & Co.ReiteratesBuy—
4 Nov 2024HC Wainwright & Co.ReiteratesBuy—
31 Oct 2024HC Wainwright & Co.ReiteratesBuy—
24 Oct 2024HC Wainwright & Co.ReiteratesBuy—
20 June 2024HC Wainwright & Co.ReiteratesBuy—
12 June 2024HC Wainwright & Co.ReiteratesBuy—
15 May 2024HC Wainwright & Co.ReiteratesBuy—
8 May 2024HC Wainwright & Co.ReiteratesBuy—
2 May 2024HC Wainwright & Co.ReiteratesBuy—
28 Feb 2024HC Wainwright & Co.MaintainsBuy—
15 Feb 2024HC Wainwright & Co.ReiteratesBuy—
10 Aug 2023HC Wainwright & Co.ReiteratesBuy—
8 Aug 2023HC Wainwright & Co.ReiteratesBuy—
7 Aug 2023HC Wainwright & Co.ReiteratesBuy—
30 May 2023HC Wainwright & Co.ReiteratesBuy—
9 May 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PTN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PTN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Palatin Technologies, Inc. (PTN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
88.1×

Cheaper than 8% of US stocks

Price / sales
1.3×

Cheaper than 63% of US stocks

Price / book
1.6×

Cheaper than 54% of US stocks

EV / EBITDA
−0.8×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
3278.8%

Higher than 99% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−40.3%

Higher than 18% of US stocks

Net margin
−48.5%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−297.2%

Higher than 5% of US stocks

Return on assets
−65.3%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PTN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PTNPalatin Technologies, Inc.$17.2M
43
PBMPsyence Biomedical Ltd.$16.5M
3
BIVIBioVie, Inc.$16.5M
22
CTXRCitius Pharmaceuticals, Inc.$16.5M
20
TPSTTempest Therapeutics, Inc.$16.6M
36
ADILAdial Pharmaceuticals, Inc.$16.3M
21
LPCNLipocine, Inc.$16.8M
36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Palatin Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PTN news & analysis

StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It

Newsfile Corp · 6 Aug 2026neutral

The article highlights roughly $2.9 billion and $10.0 billion of recent acquisitions in the rare-endocrine space and notes that IMCIVREE, the only approved MC4R agonist for acquired hypothalamic obesity and Bardet-Biedl syndrome, posted $71.3 million in global second-quarter 2026 revenue, up 19% sequentially. It states that Palatin Technologies is developing the next generation of this drug class.

Why it matters — A PTN watcher would care because the article frames market demand and commercial traction for MC4R agonists, the drug class Palatin is developing.

FAQ

Frequently asked questions about PTN stock

What is the PTN stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Palatin Technologies, Inc. have a median 12-month price target of $53, with estimates ranging from $48 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PTN stock a buy right now?

Of the 3 analysts covering Palatin Technologies, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Palatin Technologies, Inc. 43 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PTN?

As at 22 Aug 2026, Palatin Technologies, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (97 of 100).

Will PTN stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +447.0% from the last close, and Ticker Nerd's factor model ranks Palatin Technologies, Inc. 43 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PTN stock forecast for 2030?

No analyst covering Palatin Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PTN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $48 to $60 over the next 12 months.

How has PTN stock performed over the past year?

Palatin Technologies, Inc. returned -3.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Palatin Technologies, Inc. do?

Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic agents targeting the melanocortin receptor system.

What is the latest news on PTN?

The most recent item we track (Newsfile Corp, 6 Aug 2026): "StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It". The article highlights roughly $2.9 billion and $10.0 billion of recent acquisitions in the rare-endocrine space and notes that IMCIVREE, the only approved MC4R agonist for acquired hypothalamic obesity and Bardet-Biedl syndrome, posted $71.3 million in global second-quarter 2026 revenue, up 19% sequentially. It states that Palatin Technologies is developing the next generation of this drug class.

Company

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic agents targeting the melanocortin receptor system. Its primary function centers on addressing unmet medical needs in inflammatory and autoimmune diseases, with a distinct focus on treatments for ocular conditions such as dry eye disease, non-infectious uveitis, and diabetic retinopathy. Palatin has established itself as a pioneer in melanocortin receptor agonist therapies, having brought Vyleesi, a first-in-class treatment for hypoactive sexual desire disorder in premenopausal women, to FDA approval. The company's research pipeline encompasses peptide, peptide mimetic, and small molecule agonist compounds, exploring both injectable and oral formulations. Notably, Palatin actively advances clinical programs for obesity, autoimmune diseases like ulcerative colitis, and various retinal and ocular disorders. Recent strategic collaborations, such as with Boehringer Ingelheim, underscore its role in innovating targeted treatments for retinal diseases. Within the market, Palatin Technologies plays a significant role by advancing specialized therapeutics that aim to resolve inflammation through mechanisms distinct from conventional immunosuppressive drugs.

CEO Dr. Carl Spana Ph.D. · 29 employees · United States · https://palatin.com